Previous 10 | Next 10 |
NuCana plc (NASDAQ:NCNA) traded today at a new 52-week low of $2.40. Approximately 461,000 shares have changed hands today, as compared to an average 30-day volume of 988,000 shares. NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by P...
Medley Management (MDLY) +79%.Orbsat Corp (OSAT) +38%.Sphere 3D (ANY) +30%.Xinyuan Real Estate XIN +26% after announcing the completion of five newly constructed properties.Zivo Bioscience (ZIVO) +21%.China HGS Real Estate (HGSH) +18%.Presidio Property Trust (SQFT) +17%.Verona Pharm...
NuCana has been on my watch list over the past year due to its intriguing ProTide platform technology, which could generate multiple oncology drugs that can outperform the current standard of care. The share price has been under pressure since January and has been ground into an attra...
EDINBURGH, United Kingdom, May 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference being held from...
Presented Encouraging Clinical Data at ASCO-GI and AACR Additional Clinical Data Announcements and Study Initiations Expected in 2021 EDINBURGH, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the first qua...
EDINBURGH, United Kingdom, April 28, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host one-on-one meetings at the 7 th Annual Truist Securities Life Sciences Summit being held...
NuCana plc (NASDAQ:NCNA) traded at a new 52-week low today of $3.95. So far today approximately 923,000 shares have been exchanged, as compared to an average 30-day volume of 188,000 shares. NuCana plc share prices have moved between a 52-week high of $7.83 and the current low of $3.95 a...
NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease...
Presented Encouraging Clinical Data for NUC-3373 and NUC-7738 Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing Raised $80 million in a Follow-on Offering Augmente...
Today, we revisit a small oncology concern from across the pond named NuCana. The company continues to advance a pipeline of improved versions of widely-prescribed chemotherapy agents. A full analysis follows in the paragraphs below. For further details see: Circling Bac...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference. Event: Jefferies Global Healthca...
EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present at TD Cowen’s 5th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Ev...
Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients who were Resistant to PD-1 Inhibitors ...